In our institution, we add daratumumab-containing regimens before ASCT for patients with insufficient response to initial induction therapy to achieve deeper response. On the other hand, engraftment syndrome (ES
Preliminary evaluation of the ongoing EMN22-trial (daratumumab monotherapy, addition of dexamethasone and bortezomib from the fourth cycle in the case of insufficient response) revealed a median OS of 9.4 months.25 There is a recent short report of a median OS of more than 12 months in Mayo ...
Our first topic will cover the importance of frontline treatment in multiple myeloma and why it is an ideal opportunity for achieving deep response. Next, we’ll shift to topics on DARZALEX® treatment, starting with the results of the MAIA trial that studied continuous treatment with frontline...
In this retrospective analysis, no analyses according to the CD38-expression and wash-out periods were possible, because of insufficient samples. Nevertheless, Nijhof et al. and Perez de Acha et al. have already shown, that a wash out period allowed the re-expansion of myeloma cells with high...
However, conventional B cell depletion with rituximab does not address tissue-resident long-lived plasma cells and is associated with insufficient treatment response in a subset of patients. Consequently, plasma cell-targeting therapies could represent an option in cases with life- or organ-threatening...
MULTIPLE myelomaDARATUMUMABOVERALL survivalMULTIVARIATE analysisSUBGROUP analysis (Experimental design)Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We ...
28, 29, 30, 31, 32, 33 Preclinical studies have also previously demonstrated heterogeneity of response of myeloma cell lines to IFN.34, 35, 36, 37 Given this, we sought to clarify whether this increased expression of ISGs contributes to cell death in these cell lines. As this effect was...
In conclusion, while DBI is efficacious in SR patients, there is insufficient data to support a benefit in HiR-MM.doi:10.1016/j.critrevonc.2020.103211Lip Leong ChongYu Yang SoonCinnie Yentia SoekojoMelissa OoiSanjay de MelCritical Reviews in Oncology/Hematology...
252-0374, Kanagawa, Japan * Correspondence: horigome@med.kitasato-u.ac.jp; Tel.: +81-042-778-8111 Abstract: Remarkable advancements have been made in the treatment outcomes of multiple myeloma (MM) patients; however, for frail elderly patients, these treatment outcomes are still insufficient. ...